• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Molecular Diagnostics for Transplant Market Analysis

    ID: MRFR/MED/10305-CR
    128 Pages
    Rahul Gotadki
    June 2023

    Molecular Diagnostics for Transplant Market Research Report Information by Product (Reagents & Kits, Instruments, and Services & Software), by Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, and Others), by End User (Hospitals and Transplant Centers, Research Laboratories & Academic Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, And...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Molecular Diagnostics for Transplant Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Analysis

    In-depth Analysis of Molecular Diagnostics for Transplant Market Industry Landscape

    Research & Development (R&D) is a complex process that demands high knowledge and skills. The journey of creating a product begins with thinking up ideas, then moves on to designing, developing, and finally testing the product. To get approval and bring the product to market, it must meet the standards set by regulatory bodies like the Food and Drug Administration (FDA) and the European Commission (CE) in various regions. Developing these products takes years of research and testing to ensure they work well. Our focus is on creating new molecular diagnostics products with advanced technology and enhancing existing ones to be more efficient and cost-effective. Market players are constantly innovating to stay technologically advanced. The manufacturing process starts by gathering raw materials from suppliers, either produced in-house or through third-party manufacturers. Compliance with government regulations, such as those from the European Union and FDA, is crucial. Cutting costs involves finding affordable alternatives for materials, automating production, optimizing key steps, and implementing solutions to maximize capacity. Quality checks are in place to monitor the finished products before they are shipped. Distribution & sales are key revenue stages. A strong distribution network, brand value, customer base, and effective sales team drive sales globally. Collaborations with local distributors expand our global footprint. In the digital age, investments in digital advertising, social media, and public relations strengthen market reach. Sales teams use digital marketing and search engine optimization to increase awareness, and seminars and knowledge sessions inform end users about new products. Post-sales services, including training, consulting, and maintenance, become active once products enter the market. Some players offer free services initially to educate users. These services are crucial for industry growth, offering better backend support, cost-effective plans, and available personnel to boost device sales. Gathering post-sales reviews through digital platforms, surveys, and direct feedback helps us improve products based on consumer insights. Our commitment to R&D, efficient manufacturing, strategic distribution, and excellent post-sales services contributes to the growth and success of molecular diagnostics products worldwide.

    Market Summary

    The Global Molecular Diagnostics for Transplant Market is projected to grow from 0.86 USD Billion in 2024 to 2.15 USD Billion by 2035, reflecting a robust growth trajectory.

    Key Market Trends & Highlights

    Molecular Diagnostics for Transplant Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate (CAGR) of 8.66% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 2.15 USD Billion, indicating substantial growth potential.
    • In 2024, the market is valued at 0.86 USD Billion, laying a solid foundation for future expansion.
    • Growing adoption of molecular diagnostics due to the increasing need for precise transplant compatibility testing is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.86 (USD Billion)
    2035 Market Size 2.15 (USD Billion)
    CAGR (2025-2035) 8.66%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Thermo Fisher Scientific Inc. (US), BioMérieux SA (France), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), Hoffmann-La Roche Ltd. (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Abbott Laboratories, Inc. (US)

    Market Trends

    Increasing prevalence of infectious diseases market growth

    There has been an increasing prevalence of infectious diseases owing to various factors such as climate change, rapid urbanization, microbial evolution, among others. Special care needs to be taken before transplantation as a transplant patient can get any type of infection caused by bacteria, viruses, fungi and parasites. These include influenza virus infection, urinary tract infection, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr virus, Human herpesvirus 6, among several others. Moreover, increasing antimicrobial resistance is also a cause of serious concern and has been adding to the increasing prevalence of infectious disease.

    For instance, according to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur in the US each year. Thus, increasing prevalence of infectious disease has driven the demand for implementation of thorough molecular diagnostics in transplantation, thereby, driving the market.

    Moreover, the number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. In 2020, according to GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), an estimated number of 19.3 million new cancer cases and about 10 million cancer deaths occurred globally.

    Hence, the growing number of cancer patients and rising incidences of infectious diseases are increasing the demand for organ transplantation.

    The increasing emphasis on personalized medicine and the need for precise donor-recipient matching are driving advancements in molecular diagnostics for transplant procedures.

    U.S. Food and Drug Administration (FDA)

    Molecular Diagnostics for Transplant Market Market Drivers

    Market Growth Projections

    The Global Molecular Diagnostics for Transplant Market Industry is projected to experience substantial growth over the next decade. With a market value of 0.86 USD Billion in 2024, it is anticipated to expand to 2.15 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 8.66% from 2025 to 2035, driven by various factors including technological advancements, increasing transplant procedures, and heightened awareness of personalized medicine. The market's expansion reflects the critical role of molecular diagnostics in enhancing transplant outcomes and patient care.

    Rising Incidence of Infectious Diseases

    The growing incidence of infectious diseases poses a challenge for transplant recipients, thereby driving the Global Molecular Diagnostics for Transplant Market Industry. Transplant patients are particularly vulnerable to infections due to immunosuppressive therapies, necessitating the need for rapid and accurate diagnostic tools to detect infections early. The demand for molecular diagnostics that can identify pathogens quickly and effectively is increasing, as timely intervention is crucial for patient survival. This trend is expected to contribute to market growth, as healthcare providers seek reliable diagnostic solutions to manage the health of transplant patients.

    Growing Awareness of Personalized Medicine

    The increasing emphasis on personalized medicine is shaping the Global Molecular Diagnostics for Transplant Market Industry. Healthcare providers and patients are becoming more aware of the benefits of tailored treatment plans based on genetic and molecular profiles. This shift towards individualized care enhances the effectiveness of transplant procedures and minimizes the risk of complications. As a result, the demand for molecular diagnostics that can provide insights into patient-specific responses to treatment is on the rise. This trend is expected to contribute significantly to the market's growth, as healthcare systems increasingly adopt personalized approaches to transplant management.

    Regulatory Support and Funding for Research

    Government initiatives and funding for research in the field of molecular diagnostics are pivotal for the Global Molecular Diagnostics for Transplant Market Industry. Regulatory bodies are increasingly recognizing the importance of molecular diagnostics in improving transplant outcomes, leading to streamlined approval processes for new diagnostic tools. Additionally, public and private funding for research and development in this area is on the rise, fostering innovation and accelerating the introduction of advanced diagnostic solutions. This supportive environment is likely to enhance market growth, as new technologies and methodologies are developed to address the complexities of transplant medicine.

    Increasing Prevalence of Transplant Procedures

    The rising incidence of organ transplant procedures globally is a primary driver for the Global Molecular Diagnostics for Transplant Market Industry. As more patients require organ transplants due to conditions such as end-stage renal disease and liver failure, the demand for effective diagnostic tools increases. In 2024, the market is valued at approximately 0.86 USD Billion, reflecting the urgent need for precise molecular diagnostics to ensure successful transplant outcomes. This trend is expected to continue, with projections indicating that the market could reach 2.15 USD Billion by 2035, highlighting the critical role of molecular diagnostics in managing transplant patients.

    Technological Advancements in Diagnostic Tools

    Innovations in molecular diagnostic technologies significantly enhance the capabilities of the Global Molecular Diagnostics for Transplant Market Industry. Advances such as next-generation sequencing and real-time PCR allow for more accurate and rapid detection of organ rejection and infection. These technologies facilitate personalized medicine approaches, improving patient outcomes and reducing healthcare costs. The integration of artificial intelligence in diagnostic processes further streamlines workflows and enhances accuracy. As these technologies evolve, they are likely to drive market growth, contributing to a projected compound annual growth rate of 8.66% from 2025 to 2035.

    Market Segment Insights

    Molecular Diagnostics for Transplant Product Insights

    The Molecular Diagnostics for Transplant Market segmentation, based on product, includes reagents & kits, instruments, and services & software. The reagents & kits segment held the largest market in 2021, with a market share of 42.77%, and is expected to register the highest CAGR from 2022 to 2030. Molecular diagnostic reagents include disease-specific kits and standard reagents that are used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more precise identification of specific pathogen strains in a patient sample.

    Standard reagents are key components of the majority of conventional molecular diagnostic procedures. Therefore, companies are now launching rapid reagents & kits to detect the novel coronavirus to fuel the growth of this market.

    March 2022 Immucor, Inc. (US) launched innovative transplant diagnostics MIA FORA NGS EXPRESS HLA Typing Software in order to provide a faster and easier NGS analysis experience.

    Molecular Diagnostics for Transplant Technology Insights

    The Molecular Diagnostics for Transplant Market data has been segmented, based on technology, by polymerase chain reaction (PCR), sequencing, microarray, and others. The polymerase chain reaction (PCR) segment held the largest market in 2021, with a market share of ~35%, reaching a market value of around 0.5 billion by 2030. The sequencing segment is expected to register the highest CAGR of 10.59% from 2022 to 2030. Polymerase Chain Reaction (PCR) technology is used to identify a disease by analyzing the genetic and proteomic parameters such as deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) in humans or the case of infections.

    Additionally, it plays a crucial role in disease diagnostics and is considered to be one of the most developed molecular techniques which have a wide range of applications in the medicine field and for broad-spectrum pathogen detection and evaluation of emerging novel infections and surveillance.

    October 2022: Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

    Figure 2: Molecular Diagnostics for Transplant Market, by Technology, 2023 & 2030 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Molecular Diagnostics for Transplant End User Insights

    Based on end user, the global molecular diagnostics for transplant industry has been segmented into the hospitals and transplant centers, research laboratories & academic institutes, and others. The hospitals and transplant centers segment held the largest market in 2021 and is expected to register the highest CAGR of 9.73% from 2022 to 2030. Hospitals and transplant centers witness significant growth due to the rising demand for novel tissue transplantation for treating organ failure, increasing demand for transplant products like tissue products, immunosuppressants, organ preservation solutions, and technological advancements.

    Healthcare-associated infections  (HAIs) occur in all settings of care, such as ambulatory clinics, hospitals as well as nursing homes, and rehabilitation facilities.

    Get more detailed insights about Molecular Diagnostics for Transplant Market Research Report—Global Forecast till 2030

    Regional Insights

    By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America molecular diagnostics for transplant market accounted for the largest market share in 2021, due to rising demand technology evolution and increasing incidences of chronic diseases that lead to an increase in organ transplants. According to research, the number of kidneys, liver, heart, lung, pancreas, and intestine transplants is increasing in the US, while the number of kidney transplants is increasing in Canada.

    Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 3: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%)  BY REGION 2023

    MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%) BY REGION 2021

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe molecular diagnostics for transplant market accounts for the second-largest market share owing to the rising prevalence of chronic diseases, including kidney, cardiovascular diseases (CVD), and respiratory diseases. Advancements in molecular diagnostics have improved the identification and understanding of specific gene defects for the appropriate organ transplant in kidney, heart, and lung failure. CVD diseases are influenced by factors such as atherosclerosis, blood clots, diabetes, a sedentary lifestyle, and obesity, which may lead to cardiac failure. In 2019, the European Society of Cardiology (ESC) Atlas estimated that Europe reports 11 million new cases suffering from CVD each year.

    Furthermore, the Germany molecular diagnostics for transplant market held the largest market share, and the UK molecular diagnostics for transplant market was the second largest to hold the market share in the Europe region.

    The Asia-Pacific molecular diagnostics for transplant market is expected to grow at a significant share from 2022 to 2030. The region's growing geriatric population demands organ transplantation, which may vary as per organ failure. In 2020, according to the World Economic Forum, China, India, and Japan had the oldest populations globally. Furthermore, it has been estimated that by 2050, one in four aged people will be living in the region. Moreover, China molecular diagnostics for transplant market held the largest market share, and the India molecular diagnostics for transplant market was the fastest growing market in the Asia-Pacific region.

    Key Players and Competitive Insights

    Major market players are spending a lot of money on R&D to increase their product lines, which will help the molecular diagnostics for transplant market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the molecular diagnostics for transplant industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

    Thermo Fisher Scientific Inc. (US) specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, and specialty diagnostics. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the laboratory's productivity. In September 2021, the company announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

    Key Companies in the Molecular Diagnostics for Transplant Market market include

    Industry Developments

    October 2022 Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

    February 2022 Bio-Techne Corporation (US) entered into an agreement with Thermo Fisher Scientific, Inc. (US) in order to develop and commercialize the ExoTRU Kidney Transplant Rejection Test.

    In September 2021 Thermo Fisher Scientific Inc. (US) announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

    Future Outlook

    Molecular Diagnostics for Transplant Market Future Outlook

    The Global Molecular Diagnostics for Transplant Market is projected to grow at 8.66% CAGR from 2024 to 2035, driven by technological advancements, increasing transplant procedures, and rising demand for personalized medicine.

    New opportunities lie in:

    • Develop next-generation sequencing platforms for enhanced donor-recipient matching.
    • Implement AI-driven analytics for predictive transplant outcomes.
    • Expand point-of-care testing solutions to improve accessibility and speed of diagnostics.

    By 2035, the market is poised for robust growth, reflecting advancements in molecular diagnostics and increased transplantation rates.

    Market Segmentation

    Molecular Diagnostics for Transplant Product Outlook

    • Reagents & Kits
    • Instruments
    • Services & Software

    Molecular Diagnostics for Transplant End User Outlook

    • Hospitals and Transplant Centers
    • Research Laboratories & Academic Institutes
    • Others

    Molecular Diagnostics for Transplant Regional Outlook

    North America
    • US
    • Canada

    Molecular Diagnostics for Transplant Technology Outlook

    • Polymerase Chain Reaction (PCR)
    • Sequencing
    • Microarray
    • Others

    Report Scope

    Report Attribute/Metric Details
    Market Size 2021 USD 0.66 billion
    Market Size 2022 USD 0.71 billion
    Market Size 2030 USD 1.40 billion
    Compound Annual Growth Rate (CAGR) 8.91% (2024-2030)
    Base Year 2023
    Forecast Period 2024-2030
    Historical Data 2018 & 2020
    Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product, Technology, End User, and Region
    Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
    Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Thermo Fisher Scientific Inc. (US), BioMérieux SA (France), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Abbott Laboratories, Inc. (US), and others
    Key Market Opportunities Growing public awareness about organ donation and transplantation
    Key Market Drivers Increasing prevalence of infectious diseasesAdvancements in molecular diagnostic techniquesIncreasing number of transplant procedures

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    How much is the molecular diagnostics for transplant market?

    The Molecular Diagnostics for Transplant Market is anticipated to reach 1.40 billion at a CAGR of 8.91% during the forecast period of 2024-2030.

    How big is the US molecular diagnostics for transplant market?

    The US is expected to hold a 35-40% share of the global market for molecular diagnostics for transplant market during the forecast period of 2024-2030.

    What is the growth rate of the molecular diagnostics for transplant market?

    The molecular diagnostics for transplant market is expected to grow at a 8.91% CAGR during the forecast period from 2024 to 2030.

    Which region held the largest market share in the molecular diagnostics for transplant market?

    The North America region market held the largest market share in molecular diagnostics for transplant market.

    Who are the key players in the molecular diagnostics for transplant market?

    The key players include Thermo Fisher Scientific Inc. (US), BioMérieux SA (France), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), F. Hoffmann-La Roche Ltd (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Abbott Laboratories, Inc. (US), and others.

    Which product segment led the molecular diagnostics for transplant market?

    The reagents & kits product segment led the product segment in the molecular diagnostics for transplant market.

    Which technology had the largest market share in the molecular diagnostics for transplant market?

    Polymerase chain reaction (PCR) technology segment had the largest market share with over 40% market share.

    1. Table of Contents
    2. Executive Summary
      1. OVERVIEW
        1. MARKET SYNOPSIS
    3. Market Introduction
      1. DEFINITION
      2. Scope of the Study
      3. RESEARCH OBJECTIVE
      4. LIST OF ASSUMPTIONS
    4. Research Methodology
      1. OVERVIEW
      2. DATA MINING
      3. SECONDARY RESEARCH
      4. PRIMARY RESEARCH
        1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
        2. BREAKDOWN OF PRIMARY RESPONDENTS
      5. FORECASTING TECHNIQUES
      6. Research Methodology FOR MARKET SIZE ESTIMATION
        1. Bottom-up Approach
        2. TOP-DOWN APPROACH
      7. DATA TRIANGULATION
      8. VALIDATION
    5. MARKET DYNAMICS
      1. OVERVIEW
      2. DRIVERS
        1. INCREASING PREVALENCE OF INFECTIOUS DISEASES
        2. ADVANCEMENTS IN MOLECULAR DIAGNOSTIC TECHNIQUES
        3. INCREASING NUMBER OF TRANSPLANT PROCEDURES
      3. RESTRAINTS
        1. STRINGENT RULES AND REGULATIONS FOR PRODUCT APPROVAL
        2. DEARTH OF SKILLED LABOR
      4. OPPORTUNITIES
        1. GROWING PUBLIC AWARENESS ABOUT ORGAN DONATION AND TRANSPLANTATION
    6. MARKET FACTOR ANALYSIS
      1. VALUE CHAIN ANALYSIS
        1. R&D AND DESIGNING
        2. MANUFACTURING
        3. DISTRIBUTION & SALES
        4. POST-SALES SERVICES AND REVIEW
      2. PORTER'S FIVE FORCES MODEL
        1. THREAT OF NEW ENTRANTS
        2. BARGAINING POWER OF SUPPLIERS
        3. THREAT OF SUBSTITUTES
        4. BARGAINING POWER OF BUYERS
        5. INTENSITY OF RIVALRY
      3. IMPACT OF COVID-19 ON GLBOAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
        1. IMPACT ON DEMAND
        2. IMPACT ON SUPPLY CHAIN
        3. IMPACT ON KEY PLAYERS
      4. QUALITATIVE OVERVIEW FOR INFECTIOUS DISEASE VIRUSES
        1. CYTOMEGALOVIRUS (CMV)
        2. EPSTEIN-BARR VIRUS (EBV)
        3. BK POLYOMAVIRUS (BKV)
        4. HUMAN HERPESVIRUS 6 (HHV-6)
        5. ADENOVIRUS
        6. HERPES SIMPLEX VIRUS (HSV)
        7. PARVOVIRUS
        8. JOHN CUNNINGHAM VIRUS (JCV)
        9. HEPATITIS E VIRUS (HEV)
        10. OTHERS
    7. GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT
      1. OVERVIEW
      2. REAGENTS & KITS
      3. INSTRUMENTS
      4. SERVICES & SOFTWARE
    8. GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY
      1. OVERVIEW
      2. POLYMERASE CHAIN REACTION (PCR)
      3. SEQUENCING
      4. MICROARRAY
      5. OTHERS
    9. GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER
      1. OVERVIEW
      2. HOSPITALS AND TRANSPLANT CENTERS
      3. RESEARCH LABORATORIES & ACADEMIC INSTITUTES
      4. OTHERS
    10. GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION
      1. INTRODUCTION
      2. NORTH AMERICA
        1. US
        2. CANADA
      3. EUROPE
        1. GERMANY
        2. UK
        3. FRANCE
        4. ITALY
        5. SPAIN
        6. REST OF EUROPE
      4. ASIA-PACIFIC
        1. JAPAN
        2. CHINA
        3. INDIA
        4. AUSTRALIA
        5. SOUTH KOREA
        6. REST OF ASIA PACIFIC
      5. REST OF THE WORLD
        1. MIDDLE EAST
        2. AFRICA
        3. LATIN AMERICA
    11. Competitive Landscape
      1. OVERVIEW
      2. COMPETITIVE BENCHMARKING
      3. MAJOR GROWTH STRATEGY IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      4. THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      5. KEY DEVELOPMENT ANALYSIS
      6. KEY DEVELOPMENTS & GROWTH STRATEGIES
        1. PRODUCT LAUNCH/ PRODUCT APPROVAL
        2. PARTNERSHIP/AGREEMENT
        3. MERGER /ACQUISTION
      7. FINANCIAL MATRIX
        1. SALES (USD MILLION), 2021
        2. R&D EXPENDITURE (USD MILLION), 2021
    12. COMPANY PROFILE
      1. BIOMÉRIEUX SA
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCT OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      2. THERMO FISHER SCIENTIFIC INC.
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCT/SERVICE OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      3. CEPHEID
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCT/SERVICE OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      4. ALTONA DIAGNOSTICS GMBH
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      5. ELITECHGROUP
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      6. F. HOFFMANN-LA ROCHE LTD
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      7. HOLOGIC, INC.
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS/SERVICES OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      8. QIAGEN N.V.
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      9. BECTON, DICKINSON AND COMPANY 
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      10. ABBOTT
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
    13. APPENDIX
      1. REFERENCES
      2. RELATED REPORTS
    14.  
    15. List of Tables and Figures
      1. LIST OF TABLES
      2. TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
      3. TABLE 2 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030(USD MILLION)
      4. TABLE 3 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR REAGENTS & KITS, BY REGION, 2018–2030(USD MILLION)
      5. TABLE 4 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR INSTRUMENTS, BY REGION, 2018–2030(USD MILLION)
      6. TABLE 5 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SERVICES & SOFTWARE, BY REGION, 2018–2030(USD MILLION)
      7. TABLE 6 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030(USD MILLION)
      8. TABLE 7 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018–2030(USD MILLION)
      9. TABLE 8 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SEQUENCING, BY REGION, 2018–2030(USD MILLION)
      10. TABLE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR MICROARRAY, BY REGION, 2018–2030(USD MILLION)
      11. TABLE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018–2030(USD MILLION)
      12. TABLE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030(USD MILLION)
      13. TABLE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2018–2030(USD MILLION)
      14. TABLE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018–2030(USD MILLION)
      15. TABLE 14 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018–2030(USD MILLION)
      16. TABLE 15 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION, 2018–2030 (USD MILLION)
      17. TABLE 16 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
      18. TABLE 17 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      19. TABLE 18 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      20. TABLE 19 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      21. TABLE 20 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      22. TABLE 21 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      23. TABLE 22 US: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      24. TABLE 23 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      25. TABLE 24 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      26. TABLE 25 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      27. TABLE 26 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
      28. TABLE 27 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      29. TABLE 28 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      30. TABLE 29 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      31. TABLE 30 GERMANY MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      32. TABLE 31 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      33. TABLE 32 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      34. TABLE 33 UK MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      35. TABLE 34 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      36. TABLE 35 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      37. TABLE 36 FRANCE MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      38. TABLE 37 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      39. TABLE 38 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      40. TABLE 39 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      41. TABLE 40 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      42. TABLE 41 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      43. TABLE 42 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      44. TABLE 43 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      45. TABLE 44 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      46. TABLE 45 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      47. TABLE 46 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      48. TABLE 47 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      49. TABLE 48 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
      50. TABLE 49 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      51. TABLE 50 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      52. TABLE 51 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      53. TABLE 52 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      54. TABLE 53 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      55. TABLE 54 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      56. TABLE 55 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      57. TABLE 56 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      58. TABLE 57 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      59. TABLE 58 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      60. TABLE 59 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      61. TABLE 60 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      62. TABLE 61 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      63. TABLE 62 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      64. TABLE 63 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      65. TABLE 64 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      66. TABLE 65 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      67. TABLE 66 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      68. TABLE 67 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      69. TABLE 68 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      70. TABLE 69 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      71. TABLE 70 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
      72. TABLE 71 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      73. TABLE 72 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      74. TABLE 73 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      75. TABLE 74 MIDDLE EAST MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      76. TABLE 75 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      77. TABLE 76 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      78. TABLE 77 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      79. TABLE 78 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      80. TABLE 79 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      81. TABLE 80 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018–2030 (USD MILLION)
      82. TABLE 81 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
      83. TABLE 82 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018–2030 (USD MILLION)
      84. TABLE 83 MAJOR PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      85. TABLE 84 MOST ACTIVE PLAYER IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      86. TABLE 85 PRODUCT LAUNCH/ PRODUCT APPROVAL
      87. TABLE 86 PARTNERSHIP/AGREEMENT
      88. TABLE 87 MERGER/ACQUISTION
      89. TABLE 88 BIOMÉRIEUX SA: PRODUCT OFFERED
      90. TABLE 89 BIOMÉRIEUX SA: KEY DEVELOPMENTS
      91. TABLE 90 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE OFFERED
      92. TABLE 91 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
      93. TABLE 92 CEPHEID: PRODUCT/SERVICE OFFERED
      94. TABLE 93 CEPHEID: KEY DEVELOPMENTS
      95. TABLE 94 ALTONA DIAGNOSTICS GMBH: PRODUCTS OFFERED
      96. TABLE 95 ALTONA DIAGNOSTICS GMBH: KEY DEVELOPMENTS
      97. TABLE 96 ELITECHGROUP: PRODUCTS OFFERED
      98. TABLE 97 ELITECHGROUP: KEY DEVELOPMENTS
      99. TABLE 98 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
      100. TABLE 99 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS
      101. TABLE 100 HOLOGIC, INC: PRODUCTS OFFERED
      102. TABLE 101 HOLOGIC INC.: KEY DEVELOPMENTS
      103. TABLE 102 QIAGEN N.V.: PRODUCTS OFFERED
      104. TABLE 103 QIAGEN N.V.: KEY DEVELOPMENTS
      105. TABLE 104 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
      106. TABLE 105 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS
      107. TABLE 106 ABBOTT: PRODUCTS OFFERED
      108. TABLE 107 ABBOTT: KEY DEVELOPMENTS   LIST OF FIGURES
      109. FIGURE 1 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET STRUCTURE
      110. FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
      111. FIGURE 3 MARKET DYNAMICS: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      112. FIGURE 4 DRIVER IMPACT ANALYSIS
      113. FIGURE 5 RESTRAINT IMPACT ANALYSIS
      114. FIGURE 6 VALUE CHAIN ANALYSIS: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      115. FIGURE 7 Porter's Five Forces Analysis: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      116. FIGURE 8 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY PRODUCT 2021
      117. FIGURE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2021 & 2030 (USD MILLION)
      118. FIGURE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2021 & 2030 (USD MILLION)
      119. FIGURE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2021 & 2030 (USD MILLION)
      120. FIGURE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION 2021 & 2030 (USD MILLION)
      121. FIGURE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY REGION, 2021
      122. FIGURE 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
      123. FIGURE 15 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
      124. FIGURE 16 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
      125. FIGURE 17 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY 2021
      126. FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS
      127. FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
      128. FIGURE 20 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET: Competitive Landscape
      129. FIGURE 21 SALES 2021
      130. FIGURE 22 R&D EXPENDITURE, 2021
      131. FIGURE 23 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT
      132. FIGURE 24 BIOMÉRIEUX SA: SWOT ANALYSIS
      133. FIGURE 25 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
      134. FIGURE 26 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
      135. FIGURE 27 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
      136. FIGURE 28 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS
      137. FIGURE 29 HOLOGIC INC.: FINANCIAL OVERVIEW SNAPSHOT
      138. FIGURE 30 QIAGEN N.V.: FINANCIAL OVERVIEW SNAPSHOT
      139. FIGURE 31 QIAGEN N.V.: SWOT ANALYSIS
      140. FIGURE 32 BECTON, DICKINSON AND COMPANY : FINANCIAL OVERVIEW SNAPSHOT
      141. FIGURE 33 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS
      142. FIGURE 34 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT

     

    Molecular Diagnostics for Transplant Market Segmentation

    Molecular Diagnostics for Transplant Product Outlook (USD Billion, 2018-2030)

    • Reagents & Kits
    • Instruments
    • Services & Software

    Molecular Diagnostics for Transplant Technology Outlook (USD Billion, 2018-2030)

    • Polymerase Chain Reaction (PCR)
    • Sequencing
    • Microarray
    • Others

    Molecular Diagnostics for Transplant End User Outlook (USD Billion, 2018-2030)

    • Hospitals and Transplant Centers
    • Research Laboratories & Academic Institutes
    • Others

    Molecular Diagnostics for Transplant Regional Outlook (USD Billion, 2018-2030)

    • North America Outlook (USD Billion, 2018-2030)

      • North America Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • North America Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • North America Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • US Outlook (USD Billion, 2018-2030)

      • US Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • US Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • US Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Canada Outlook (USD Billion, 2018-2030)

      • Canada Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Canada Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Canada Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

    • Europe Outlook (USD Billion, 2018-2030)

      • Europe Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Europe Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Europe Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Germany Outlook (USD Billion, 2018-2030)

      • Germany Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Germany Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Germany Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • France Outlook (USD Billion, 2018-2030)

      • France Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • France Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • France Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • UK Outlook (USD Billion, 2018-2030)

      • UK Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • UK Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • UK Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Italy Outlook (USD Billion, 2018-2030)

      • Italy Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Italy Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Italy Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Spain Outlook (USD Billion, 2018-2030)

      • Spain Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Spain Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Spain Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Rest of Europe Outlook (USD Billion, 2018-2030)

      • Rest of Europe Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Rest of Europe Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Rest of Europe Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

    • Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Asia-Pacific Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Asia-Pacific Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Asia-Pacific Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • China Outlook (USD Billion, 2018-2030)

      • China Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • China Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • China Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Japan Outlook (USD Billion, 2018-2030)

      • Japan Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Japan Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Japan Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • India Outlook (USD Billion, 2018-2030)

      • India Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • India Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • India Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • South Korea Outlook (USD Billion, 2018-2030)

      • South Korea Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • South Korea Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • South Korea Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Australia Outlook (USD Billion, 2018-2030)

      • Australia Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Australia Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Australia Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Rest of Asia-Pacific Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Rest of Asia-Pacific Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Rest of Asia-Pacific Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

    • Rest of the World Outlook (USD Billion, 2018-2030)

      • Rest of the World Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Rest of the World Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Rest of the World Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Middle East Outlook (USD Billion, 2018-2030)

      • Middle East Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Middle East Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Middle East Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Africa Outlook (USD Billion, 2018-2030)

      • Africa Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Africa Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Africa Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

      • Latin America Outlook (USD Billion, 2018-2030)

      • Latin America Molecular Diagnostics for Transplant by Product
        • Reagents & Kits
        • Instruments
        • Services & Software
      • Latin America Molecular Diagnostics for Transplant by Technology
        • Polymerase Chain Reaction (PCR)
        • Sequencing
        • Microarray
        • Others
      • Latin America Molecular Diagnostics for Transplant by End User
        • Hospitals and Transplant Centers
        • Research Laboratories & Academic Institutes
        • Others

     

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027